Gilad Oren — SEC Form 4 filings
SEC reporting owner CIK 1929300. 10 Form 4 filings on record with FilingPulse; latest filed 2026-03-16.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-03-14 to 2026-03-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 6 filings — 37,500 shares, $55,353 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: purchase of 28,100 shares @ $0.89 ($25,009) in Aprea Therapeutics, Inc., filed 2026-02-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | President/CEO, Director | 10 | 8 legs · 37,500 sh · $55,353 | — | 11 |
Form 4 filings — Gilad Oren
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-16 | 4 | Aprea Therapeutics, Inc. (APRE) | Grant/award (A): 20,175 @ $0 · Grant/award (A): 80,700 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 28,100 @ $0.89 · Purchase (P): 28,100 (derivative) | EDGAR |
| 2025-12-11 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 21,459 (derivative) @ $1.17 · Purchase (P): 21,459 (derivative) | EDGAR |
| 2025-04-04 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 3,003 @ $1.87 · Purchase (P): 2,497 @ $1.80 | EDGAR |
| 2025-03-31 | 4 | Aprea Therapeutics, Inc. (APRE) | Grant/award (A): 6,725 @ $0 · Grant/award (A): 26,900 (derivative) @ $0 | EDGAR |
| 2024-10-24 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 500 @ $3.92 | EDGAR |
| 2024-10-16 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 250 @ $2.90 | EDGAR |
| 2024-10-15 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 150 @ $2.54 · Purchase (P): 1,000 @ $2.59 | EDGAR |
| 2024-03-28 | 4 | Aprea Therapeutics, Inc. (APRE) | Grant/award (A): 6,725 @ $0 · Grant/award (A): 26,900 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | Aprea Therapeutics, Inc. (APRE) | Purchase (P): 2,000 @ $7.29 · Purchase (P): 1,000 (derivative) · Purchase (P): 1,000 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1929300 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →